Fred Saad
University of Montreal Hospital Center · CHUM-Centre Hospitalier de l'Universite de Montreal, Canada · CHUM
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fred Saad as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:26 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05171816 · Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)AstraZeneca · active not recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph2NCT04663997 · 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate CancerCanadian Cancer Trials Group · active not recruiting · Prostate Cancer · study chair
- Ph2NCT03764540 · Docetaxel Versus Cabazitaxel Post Abiraterone or EnzalutamideCentre hospitalier de l'Université de Montréal (CHUM) · terminated · Metastatic Prostate Cancer · principal investigator
- Ph3NCT03732820 · Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerAstraZeneca · active not recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
- N/ANCT02730338 · INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)Movember Foundation · unknown · Metastatic Prostate Cancer · study chair
- Ph2NCT00327340 · Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPCAchieve Life Sciences · completed · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:26 UTC. The ranking covers the 200 most relevant of 215 PubMed records, and a shared surname and initials can bring in a namesake. All 215 on PubMed
- Increased survival with enzalutamide in prostate cancer after chemotherapy.N Engl J Med · 20123,750 citationsRCR 102.0
- Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med · 20113,643 citationsRCR 95.7
- Enzalutamide in metastatic prostate cancer before chemotherapy.N Engl J Med · 20142,392 citationsRCR 70.7
- Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med · 20132,334 citationsRCR 67.7
- Olaparib for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med · 20201,923 citationsRCR 83.2
- A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.J Natl Cancer Inst · 20021,278 citationsRCR 28.1
- 1,127 citationsRCR 30.7
- 1,126 citationsRCR 35.2
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.N Engl J Med · 20181,042 citationsRCR 38.8
- Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.J Natl Cancer Inst · 2004884 citationsRCR 19.8